DexCom, Inc.

DXCM Healthcare Medical Devices

DexCom, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue grew 13.1%, EPS grew 41.3%, free cash flow fell 11.7% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

86.06 1.65 −1.88%
Market cap
$33.1B
P/E
33.2×
Fwd P/E
29.8×
Dividend yield
—
F-score
8/9
Altman Z
6.43
Beneish M
−2.70
Dividend safety
n/a

DexCom, Inc. (DXCM) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, DexCom, Inc. (DXCM) trades at a EV/FCF of 23.5×. Over the past ten years it has ranged from −2,702× (December 2017) to 14,049× (January 2017); the current reading is higher than 20% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 24.1× (49.50%)
FY2024 47.6× (49.20%)
FY2023 93.8× (35.35%)
FY2022 145× 670.12%
FY2021 18.8× (84.62%)
FY2020 122× (15.41%)
FY2019 145× (20.33%)
FY2018 182× (1.30%)
FY2017 184× (98.06%)
FY2016 9,495× 2,220.17%

Quarterly newest first

Period EV/FCF Change
Jun 2026 18.4× 10.40%
Mar 2026 16.6× (30.83%)
Dec 2025 24.1× 2.15%
Sep 2025 23.5× (59.64%)
42 more quarters

Against its own ten years

Low −2,702× High 14,049×
Ten-year median 139×
Current reading's percentile 16

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on DXCM